

ODMA\MHODMA\MAA\gci212370.1
CSE/DBS/cram
07/05/01

COPY COPY

July 9, 2001
PATENT APPLICATION
DOCKET NO.: 0975.1005-005

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Junming Le, Jan Vilcek, Peter Daddona, John Ghrayeb, David M. Knight and Scott Siegel

Application No.: 09/756,398 Group Art Unit: 1642

Filed: January 8, 2001 Examiner: Not Assigned

Title: ANTI-TNF ANTIBODIES AND PEPTIDES OF HUMAN TUMOR NECROSIS FACTOR

| CERTIFICATE OF MAILING | |
|---|------------------------------|
| I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as First Class Mail in an envelope addressed to Assistant Commissioner for Patents, Washington, D.C. 20231 | |
| on July 5, 2001 | <i>Christina M. Mcweeney</i> |
| Date | Signature |
| Christina M. Mcweeney | |
| Typed or printed name of person signing certificate | |

INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

This Information Disclosure Statement is submitted:

- ☐ under 37 CFR 1.129(e), or
(First/Second submission after Final Rejection)
- ☒ under 37 CFR 1.97(b), or
(Within any one of the following time periods: three months of filing national application (other than a CIPA) or date of entry of the national stage in an international application, or before the mailing date of a first office action on the merits in a non-provisional application, including a CIPA, or a Request for Continued Examination)
- ☐ under 37 CFR 1.97(c) together with either:
 - ☐ a Statement under 37 CFR 1.97(e), as checked below, or
 - ☐ a \$180.00 fee under 37 CFR 1.17(p), or
(After the 37 CFR 1.97(c) time period, but before final action or notice of allowance, whichever occurs first)
- ☐ under 37 CFR 1.97(d) together with:
 - ☐ a Statement under 37 CFR 1.97(e), as checked below, and
 - ☐ a \$180.00 fee under 37 CFR 1.17(p), or
(Filed after final action or notice of allowance, whichever occurs first, but on or before payment of the issue fee)
- ☐ under 37 CFR 1.97(i):
Applicant requests that the IDS and cited reference(s) be placed in the application filewrapper.

09/756.398

-2-

Statement Under 37 CFR 1.97(e)

- ☐ Each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement; or
- ☐ No item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned, after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of this Information Disclosure Statement.

Statement Under 37 CFR 1.704(d) (Patent Term Adjustment)

Applies to original applications (other than design) filed on or after May 29, 2000

- ☐ Each item of information contained in the information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart application and this communication was not received by any individual designated in § 1.56(c) more than thirty days prior to the filing of the Information Disclosure Statement.
- ☒ Enclosed herewith is form PTO-1449:
- ☐ Copies of the cited references are enclosed.
- ☒ Copies of cited references are enclosed except those entered in prior applications. U.S. Application No. 09/133,119 and Application No. 08/192,093, to which priority under 35 U.S.C. 120 is claimed. The earlier applications contains copies of the cited references.
- ☐ The listed references were cited in the enclosed International Search Report in a counterpart foreign application
- ☐ The "concise explanation" requirement (non-English references) for reference(s) ☐ under 37 CFR 1.98(a)(3) is satisfied by:
- ☐ the explanation provided on the attached sheet.
- ☐ the explanation provided in the Specification.
- ☐ submission of the enclosed International Search Report.
- ☐ the enclosed English language abstract.

- ☒ Applicant requests that the following pending applications be considered:

Examiner's
initials:

U.S. Patent Application No. 09/756,161, by Junming Le, Jan Vilcek, Peter Daddona, John Ghayeb, David M. Knight and Scott Siegel, filed January 8, 2001, Docket No.: 0975.1005-007

09/756.398

-3-

KAC

U.S. Patent Application No. 09/756.301, by Junming Le, Jan Vilcek, Peter Daddona, John Ghayeb, David M. Knight and Scott Siegel, filed January 8, 2001, Docket No.: 0975.1005-008

Thom G. Gamble
Examiner

7/15/2004
Date

- [X] A copy of each above-cited application, including the current claims, is enclosed.
- [] A copy of each above-cited application, including the current claims, is enclosed, except those entered in prior application, U.S. Application No. [], to which priority under 35 U.S.C. 120 is claimed.

The Examiner is requested to return a copy of the above list of pending applications indicating which references were considered with the next office communication.

It is requested that the information disclosed herein be made of record in this application.

Method of payment:

- [] A check for the fee noted above is enclosed, or the fee has been included in the check with the accompanying Reply. A copy of this Statement is enclosed.
- [] Please charge Deposit Account 08-0380 in the amount of \$[]. A copy of this Statement is enclosed.
- [X] Please charge any deficiency in fees and credit any overpayment to Deposit Account 08-0380.

Respectfully submitted,

HAMILTON, BROOK, SMITH & REYNOLDS, P.C.

By Deirdre E. Sanders
Deirdre E. Sanders
Registration No.: 42,122
Telephone: (781) 861-6240
Facsimile: (781) 861-9540

Lexington, Massachusetts 02421-4799

Dated: July 5, 2004

@PFFDesktop:ODMA/MHODMA/MA
 CSE/DES/ICZ/ci.nm/dc)
 03/29/02

FILE COPY

PATENT APPLICATION
 DOCKET NO.: 0975.1005-006

COPY

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Junming Le, Jan Vileck, Peter Daddona, John Ghayeb, David M. Knight and
 Scott Siegel


Application No.: 09/756,398

Group Art Unit: 1642

Filed: January 8, 2001

Examiner: Not assigned

Title: Anti-TNF Antibodies and Peptides of Human Tumor Necrosis Factor



SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents
 P.O. Box 2327
 Arlington, VA 22202

Sir:

This Information Disclosure Statement is submitted:

☐ under 37 CFR 1.129(a), or

(First/Second submission after Final Rejection)

☒ under 37 CFR 1.97(b), or

(Within any one of the following time periods: three months of filing national application (other than a CPA) or date of entry of the national stage in an international application; or before the mailing date of a first office action on the merits in a non-provisional application, including a CPA, or a Request for Continued Examination).

☐ under 37 CFR 1.97(c) together with either:

☐ a Statement under 37 CFR 1.97(e), as checked below, or

☐ a \$180.00 fee under 37 CFR 1.17(p), or

(After the 37 CFR 1.97(b) time period, but before final action or notice of allowance, whichever occurs first)

☐ under 37 CFR 1.97(d) together with:

☐ a Statement under 37 CFR 1.97(e), as checked below, and

☐ a \$180.00 fee under 37 CFR 1.17(p), or

(Filed after final action or notice of allowance, whichever occurs first, but on or before payment of the issue fee)

☐ under 37 CFR 1.97(i):

Applicant requests that the IDS and cited reference(s) be placed in the application filewrapper.

(Filed after payment of issue fee)

09/756.398

-2-

Statement Under 37 CFR 1.97(e)

- ☐ Each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement, or
- ☐ No item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned, after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of this Information Disclosure Statement.

Statement Under 37 CFR 1.704(d) (Patent Term Adjustment)

Applies to original applications (other than design) filed on or after May 29, 2000

- ☐ Each item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart application and this communication was not received by any individual designated in § 1.56(c) more than thirty days prior to the filing of the Information Disclosure Statement.
- ☒ Enclosed herewith is form PTO-1449:
- ☒ Copies of the cited references are enclosed.
- ☐ Copies of cited references are enclosed except those entered in prior application, U.S. Application No. [], to which priority under 35 U.S.C. 120 is claimed. [The earlier application contains copies of the cited references.]
- ☐ The listed references were cited in the enclosed International Search Report in a counterpart foreign application.
- ☐ The "concise explanation" requirement (non-English references) for reference(s) [] under 37 CFR 1.98(a)(3) is satisfied by:
- ☐ the explanation provided on the attached sheet.
 - ☐ the explanation provided in the Specification.
 - ☐ submission of the enclosed International Search Report.
 - ☐ submission of the enclosed English-language version of a foreign Search Report and/or foreign Office Action.
 - ☐ the enclosed English language abstract.

(09/756,398

-3-

[X] Applicant requests that the following non-published pending applications be considered:

Examiner's
InitialsKAC

U.S. Patent Application No. 09/766,535, by Junming Le, Jan Vilcek, Peter Daddona, John Ghrayeb, David M. Knight and Scott Siegel, filed January 18, 2001, Docket No.: 0975.1005-010

KAC

U.S. Patent Application No. 09/897,724, by Junming Le, Jan Vilcek, Peter Daddona, John Ghrayeb, David M. Knight and Scott Siegel, filed July 2, 2001, Docket No.: 0975.1005-012

KAC

U.S. Patent Application No. 09/927,703, by Junming Le, Jan Vilcek, Peter Daddona, John Ghrayeb, David M. Knight and Scott Siegel, filed August 10, 2001, Docket No.: 0975.1005-013

KAC

U.S. Patent Application No. 10/010,229, by Junming Le, Jan Vilcek, Peter Daddona, John Ghrayeb, David M. Knight and Scott Siegel, filed December 7, 2001, Docket No.: 0975.1005-014

KAC

U.S. Patent Application No. 10/043,450, by Junming Le, Jan Vilcek, Peter Daddona, John Ghrayeb, David M. Knight and Scott Siegel, filed January 10, 2002, Docket No.: 0975.1005-015

KAC

U.S. Patent Application No. 10/044,534, by Junming Le, Jan Vilcek, Peter Daddona, John Ghrayeb, David M. Knight and Scott Siegel, filed January 10, 2002, Docket No.: 0975.1005-016

KAC

U.S. Patent Application No. 10/043,432, by Junming Le, Jan Vilcek, Peter Daddona, John Ghrayeb, David M. Knight and Scott Siegel, filed January 10, 2002, Docket No.: 0975.1005-017

KAC

U.S. Patent Application No. 10/043,436, by Junming Le, Jan Vilcek, Peter Daddona, John Ghrayeb, David M. Knight and Scott Siegel, filed January 10, 2002, Docket No.: 0975.1005-018


Examiner

7/15/2004
Date

[X] A copy of each above-cited application, including the current claims, is enclosed.

[] A copy of each above-cited application, including the current claims, is enclosed, except those entered in prior application, U.S. Application No. [], to which priority under 35 U.S.C. 120 is claimed.

The Examiner is requested to return a copy of the above list of pending applications indicating which references were considered with the next office communication.

It is requested that the information disclosed herein be made of record in this application.

09/756,398

-4-


Method of payment:

- [] A check for the fee noted above is enclosed, or the fee has been included in the check with the accompanying Reply. A copy of this Statement is enclosed.
- [] Please charge Deposit Account 08-0380 in the amount of \$[]. A copy of this Statement is enclosed.
- [X] Please charge any deficiency in fees and credit any overpayment to Deposit Account 08-0380.

Respectfully submitted,

HAMILTON, BROOK, SMITH & REYNOLDS, P.C.

By



Deirdre E. Sanders

Registration No.: 42,122

Telephone: (978) 341-0036

Facsimile: (978) 341-0136

Concord, MA 01742-9133

Dated:

March 29, 2004

JUN-22-2004 TUE 05:26 PM

Sept 13, 2002

FAX NO.

P. 10

@PFDesktop\ODMA\MHODMA\Man...333425;1
AOC\DES\CZ\hij
September 10, 2002

PATENT APPLICATION
DOCKET NO.: 0975.1005-006

COPY

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Junming Le, Jan Vilcek, Peter Daddona, John Ghayeb, David M. Knight and Scott Siegel

Application No.: 09/756,398 Group Art Unit: 1642

Filed: January 8, 2001 Examiner: Karen Canella

Title: ANTI-TNF ANTIBODIES AND PEPTIDES OF HUMAN TUMOR NECROSIS FACTOR

| | |
|---|-----------------------|
| CERTIFICATE OF MAILING | |
| I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as First Class Mail in an envelope addressed to Assistant Commissioner for Patents, P.O. Box 2327, Arlington, VA 22202 | |
| on 9-10-02 | <i>Linda M. Amato</i> |
| Date | Signature |
| Linda M. Amato | |
| Typed or printed name of person signing certificate | |

SECOND SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents
P.O. Box 2327
Arlington, VA 22202 20231 20231

Sir:

This Information Disclosure Statement is submitted:

- ☐ under 37 CFR 1.129(a), or
(First/Second submission after Final Rejection)
- ☐ under 37 CFR 1.97(b), or
(Within any one of the following time periods: three months of filing national application (other than a CIPA) or date of entry of the national stage in an international application; or before the mailing date of a first office action on the merits in a non-provisional application, including a CIPA, or a Request for Continued Examination)
- ☒ under 37 CFR 1.97(c) together with either:
- ☐ a Statement under 37 CFR 1.97(e), as checked below, or
- ☒ a \$180.00 fee under 37 CFR 1.17(p), or
(After the 37 CFR 1.97(b) time period, but before final action or notice of allowance, whichever occurs first)
- ☐ under 37 CFR 1.97(d) together with:
- ☐ a Statement under 37 CFR 1.97(e), as checked below, and
- ☐ a \$180.00 fee under 37 CFR 1.17(p), or
(Filed after final action or notice of allowance, whichever occurs first, but on or before payment of this issue fee)
- ☐ under 37 CFR 1.97(i):
Applicant requests that the IDS and cited reference(s) be placed in the application file wrapper.
(Filed after payment of issue fee)

09/756,398

-2-

Statement Under 37 CFR 1.97(e)

- [] Each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement; or
- [] No item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned, after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of this Information Disclosure Statement.

Statement Under 37 CFR 1.704(d) (Patent Term Adjustment)

Applies to original applications (other than design) filed on or after May 29, 2000

- [] Each item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart application and this communication was not received by any individual designated in § 1.56(c) more than thirty days prior to the filing of the Information Disclosure Statement.

- [X] Enclosed herewith is form PTO-1449:

[X] Copies of the cited references are enclosed.

[] Copies of cited references are enclosed except those entered in prior applications, U.S. Application No. [], to which priority under 35 U.S.C. 120 is claimed. The earlier applications contains copies of the cited references.

[] The listed references were cited in the enclosed International Search Report in a counterpart foreign application.

[] The "concise explanation" requirement (non-English references) for reference(s) [] under 37 CFR 1.98(a)(3) is satisfied by:

[] the explanation provided on the attached sheet.

[] the explanation provided in the Specification.

[] submission of the enclosed International Search Report.

[] the enclosed English language abstract.

- [X] Applicant requests that the following pending applications be considered:

Examiner's Initials

KAL

U.S. Patent Application No. 10/176,460, by Junming Le, Jan Vilcek, Peter Daddona, John Ghayeb, David M. Knight and Scott Siegel, filed June 20, 2002, Docket No.: 0975.1005-019

KAL

U.S. Patent Application No. 10/187,121, by Junming Le, Jan Vilcek, Peter Daddona, John Ghayeb, David M. Knight and Scott Siegel, filed June 28, 2002, Docket No.: 0975.1005-020

KAL

U.S. Patent Application No. 10/186,559, by Junming Le, Jan Vilcek, Peter Daddona, John Ghayeb, David M. Knight and Scott Siegel, filed June 28, 2002, Docket No.:

09/756,398

-3-

KAL

U.S. Patent Application No. 10/198,845, by Junming Le, Jan Vilcek, Peter Daddona, John Ghayeb, David M. Knight and Scott Siegel, filed July 18, 2002, Docket No.: 0975.1005-022

KAL

U.S. Patent Application No. 10/200,795, by Junming Le, Jan Vilcek, Peter Daddona, John Ghayeb, David M. Knight and Scott Siegel, filed July 22, 2002, Docket No.: 0975.1005-023

KAL

U.S. Patent Application No. 10/208,195, by Junming Le, Jan Vilcek, Peter Daddona, John Ghayeb, David M. Knight and Scott Siegel, filed July 29, 2002, Docket No.: 0975.1005-024

Karen D. Gamelle
Examiner7/15/2004
Date

- [X] The specification for the above cited co-pending applications is identical to the present specification (09/756,398). Therefore, only a copy of the current claims for each application is enclosed. Copies of the specifications of the co-pending applications will be provided upon request.
- [] A copy of each above-cited application, including the current claims, is enclosed, except those entered in prior application, U.S. Application No. [], to which priority under 35 U.S.C. 120 is claimed.

The Examiner is requested to return a copy of the above list of pending applications indicating which references were considered with the next office communication.

It is requested that the information disclosed herein be made of record in this application.

Method of payment:

- [X] A check for the fee noted above is enclosed, or the fee has been included in the check with the accompanying Reply. A copy of this Statement is enclosed.
- [] Please charge Deposit Account 08-0380 in the amount of \$[]. A copy of this Statement is enclosed.
- [X] Please charge any deficiency in fees and credit any overpayment to Deposit Account 08-0380.

Respectfully submitted,

HAMILTON, BROOK, SMITH & REYNOLDS, P.C.

By

Deirdre E. Sanders
Deirdre E. Sanders
Registration No.: 42,122
Telephone: (978) 341-0036
Facsimile: (978) 341-0136

Concord, Massachusetts 01742-9133

April 2, 2002

G:\Franktop\1\CDMA\MSHOMA\1\manage

PTO-1449 REFERENCE

INFORMATION DISCLOSURE CITATION
IN AN APPLICATION

September 10, 2002

(Use several sheets if necessary)

ATTORNEY DOCKET NO.

0975.100.00

APPLICATION NO.

56,398

APPLICANT
Junning Le et al.FILING DATE
January 5, 2001GROUP
1642

U.S. PATENT DOCUMENTS

| EXAM- INER INITIAL | | DOCUMENT NUMBER | DATE | NAME | CLASS | SUB- CLASS | FILING DATE IF APPROPRIATE |
|--------------------------|-----|-----------------|----------|---------------------|-------|---------------|----------------------------------|
| KAC | AF | 5,233,395 | 06/29/93 | Gero | | | |
| | AG | 5,436,154 | 07/25/95 | Barbanti et al. | | | |
| | AH | 5,654,407 | 08/05/97 | Boyle et al. | | | |
| | AI | 5,700,788 | 12/23/97 | Mongelli et al. | | | |
| | AJ | 5,730,975 | 03/24/98 | Hotamisligil et al. | | | |
| | AK | 5,741,488 | 04/21/98 | Feldman et al. | | | |
| | AA2 | 5,776,947 | 07/07/98 | Kroemer et al. | | | |
| | AB2 | 6,015,558 | 01/18/00 | Hotamisligil et al. | | | |
| | AC2 | 6,172,202 B1 | 01/09/01 | Marcucci et al. | | | |
| ✓ | AD3 | 6,194,451 B1 | 02/27/01 | Alpegiani et al. | | | |

FOREIGN PATENT DOCUMENTS

| | | DOCUMENT NUMBER | DATE | COUNTRY | CLASS | SUB- CLASS | TRANSLATION YES NO |
|-----|-----|-----------------|-----------|---------|-------|---------------|-----------------------|
| KAC | ALA | 0 288 088 B1 | 26 OCT 88 | EPO | | | |
| KAC | AMS | 0 351 789 B1 | 24 JAN 90 | EPO | | | |
| KAC | ANS | 0 453 898 A2 | 30 OCT 91 | EPO | | | X |

OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, Etc.)

| | | |
|-----|-----|--|
| KAC | ARE | Oliff, A., et al., "Tumors Secreting Human TNF/Cachectin Induce Cachexia in Mice," Cell, 50:555-563 (1987). |
| | ASB | Mule, J.J., et al., "Antitumor Activity of Recombinant Interleukin 6 in Mice," The Journal of Experimental Medicine, 171:629-636 (1990). |
| | ATS | Luettig, B., et al., "Evidence For The Existence Of Two Forms Of Membrane Tumor Necrosis Factor: An Integral Protein And A Molecule Attached To Its Receptor," The Journal of Immunology, 143:4034-4038 (1989). |
| ✓ | AUB | Barbuto, J.A.M., et al., "Production of neutralizing antibodies to tumor necrosis factor by human tumor-infiltrating B lymphocytes," Proceedings of the American Association for Cancer Research, 34:487, Abstract 2904, (1993). |

EXAMINER

Kam G. Goulet

DATE CONSIDERED

7/15/2004

Sheet 2 of 4

| | | | | | |
|--|-----------------|--|---------|-------------------------------|---------------|
| TTC-1189 EXPEDITION | | ATTORNEY DOCKET NO. 0975.1005-006 | | APPLICATION NO. 09/756,398 | |
| INFORMATION DISCLOSURE CITATION IN AN APPLICATION | | | | | |
| September 10, 2002 (Use several sheets if necessary) | | | | | |
| FILING DATE January 8, 2001 | | | | | |
| GROUP 1642 | | | | | |
| U.S. PATENT DOCUMENTS | | | | | |
| EXAM- INER FILE | DOCUMENT NUMBER | DATE | NAME | CLASS | SUB- CLASS |
| | | | | | |
| FOREIGN PATENT DOCUMENTS | | | | | |
| | DOCUMENT NUMBER | DATE | COUNTRY | CLASS | SUB- CLASS |
| | | | | | |
| ✓ | 0 585 705 A1 | 09 MAR 94 | EPO | | |
| | 0 614 984 A2 | 14 SEP 94 | EPO | | |
| | 0 662 836 B1 | 26 JUL 95 | EPO | | |
| | WO 89/08460 | 21 SEP 89 | PCT | | |
| | WO 90/01950 | 08 MAR 90 | PCT | | |
| | WO 91/04054 | 04 APR 91 | PCT | | |
| | WO 91/01472 | 06 FEB 92 | PCT | | |
| | WO 93/11236 | 10 JUN 93 | PCT | | |
| | WO 94/08609 | 28 APR 94 | PCT | | |
| ✓ | WO 94/08615 | 28 APR 94 | PCT | | |
| OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) | | | | | |
| ✓ | AV1 | Bendtsen, K., et al., "Auto-Antibodies To IL-1 α and TNF α In Normal Individuals And In Infectious And Immunoinflammatory Disorders," <i>The Physiological and Pathological Effects of Cytokines</i> , 108:447-452 (1990). | | | |
| | ANS | Fonsgaard, A., et al., "Auto-Antibodies To Tumour Necrosis Factor α In Healthy Humans And Patients With Inflammatory Diseases And Gram-Negative Bacterial Infections," <i>Scand. J. Immunol.</i> , 30:219-223 (1989). | | | |
| | ANB | James, K. and Esll, G.T., "Human Monoclonal Antibody Production Current Status And Future Prospects," <i>Journal of Immunological Methods</i> , 100:5-40 (1987). | | | |
| | AYB | Alberts, B. et al., <i>Molecular Biology of the Cell</i> , Garland Publishing Inc., pp 162-183 (1983). | | | |
| | ACS | Simpson, S.Q., et al., "Role Of Tumor Necrosis Factor In Sepsis And Acute Lung Injury," <i>Critical Care Clinics</i> , 5:27-47 (1989). | | | |
| ✓ | AF9 | Bendtsen, K., et al., "Native inhibitors (autoantibodies) of IL-1 α and TNF," <i>Immunology Today</i> , 10(7):222 (1989). | | | |
| EXAMINER | | DATE CONSIDERED | | | |
| Karen A. Gaudin | | 7/15/2007 | | | |

Sheet 3 of 4

| | | | |
|--|------|--|-------------------------------|
| PTO-1447 REPRODUCED | | ATTORNEY DOCKET NO. 0975.1005-006 | APPLICATION NO. 09/756,398 |
| INFORMATION DISCLOSURE CITATION IN AN APPLICATION | | APPLICANT Junming Le et al. | |
| September 10, 2002 | | FILING DATE January 8, 2001 | GROUP 1642 |
| (Use several sheets if necessary) | | | |
| OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) | | | |
| 144 | A25 | Davenport, C., et al., "Stimulation Of Human B Cells Specific For Candida Albicans For Monoclonal Antibody Production," <i>FEMS Microbiol Immunol</i> , 4(6):335-343 Abstract (1992). | |
| 145 | P75 | Pennica, D., et al., "Human tumour necrosis factor: precursor structure, expression and homology to lymphotoxin," <i>Nature</i> , 312(20/27):724-729 (1984). | |
| 146 | A09 | Gray, P.W., et al., "Cloning and expression of cDNA for human lymphotoxin, a lymphokine with tumour necrosis activity," <i>Nature</i> , 312(20/27):721-724 (1984). | |
| 147 | AV9 | Petersen, C.M., et al., "Bioactive human recombinant tumor necrosis factor- α : an unstable dimer?," <i>Eur. J. Immunol.</i> , 19:1887-1894 (1989). | |
| 148 | AW4 | Smith, C. A., et al., "A Receptor for Tumor Necrosis Factor Defines an Unusual Family of Cellular and Viral Proteins," <i>Science</i> , 248:1019-1023 (1990). | |
| 149 | AN9 | Brennan, F.M., et al., "Inhibitory Effect Of TNF α Antibodies On Synovial Cell Interleukin-1 Production In Rheumatoid Arthritis," <i>The Lancet</i> , 244-247 (1988). | |
| 150 | AV5 | Hahn, T., et al., "Use of monoclonal antibodies to a human cytotoxin for its isolation and for examining the self-induction of resistance to this protein," <i>Proc. Natl. Acad. Sci. USA</i> 82:3814-3818 (1985). | |
| 151 | AP9 | Grau, G.E., et al., "Tumor Necrosis Factor (Cachectin) as an Essential Mediator in Murine Cerebral Malaria," <i>Science</i> , 237:1210-1212 (1987). | |
| 152 | AB10 | Barbanti, E., et al., "A high-affinity neutralizing anti-human TNF- α monoclonal antibody that cross-reacts with human TNF- β ," Abstracts, March 6th-9th (1991). | |
| 153 | A210 | Jones, E.Y., et al., "Structure of tumour necrosis factor," <i>Nature</i> , 338:225-228 (1989). | |
| 154 | AT10 | Clark, W. R., "Types of Antibody Reactions," In <i>The Experimental Foundations of Modern Immunology</i> , (NY: John Wiley & Sons, Inc.) 4th Ed., pp 143-155 (1991). | |
| 155 | A020 | Beutler, B., et al., "Cachectin and tumour necrosis factor as two sides of the same biological coin," <i>Nature</i> , 320:584-588 (1986). | |
| 156 | AV10 | Folks, T. M., et al., "Tumor Necrosis factor α induces expression of human immunodeficiency virus in a chronically infected T-cell clone," <i>Proc. Natl. Acad. Sci. USA</i> , 86:2365-2368 (1989). | |
| 157 | AW10 | Hird, V., et al., "Immunotherapy with Monoclonal Antibodies," In <i>Genes and Cancer</i> (John Wiley & Sons, Ltd.) (1990). | |
| 158 | A210 | Rhein, R., "Another sepsis drug down-Immunex' TNF receptor," <i>Biotechnology Newswatch</i> , Monday, October 4, 1993, pp. 1,3. | |
| EXAMINER | | DATE CONSIDERED | |
| Jann J. Canella | | 7/15/2004 | |

Sheet 4 of 4

| | | | |
|--|------|--|-------------------------------|
| PTO-1445 REPRODUCED | | ATTORNEY DOCKET NO. 0975.1005-006 | APPLICATION NO. 09/756,398 |
| INFORMATION DISCLOSURE CITATION IN AN APPLICATION | | APPLICANT Junming Le et al. | |
| September 10, 2002 (Use several sheets if necessary) | | FILING DATE JANUARY 8, 2001 | GROUP 1642 |
| OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) | | | |
| 1AC | AY10 | Boyle, P., et al., "A Novel Monoclonal Human IgM Autoantibody which Binds Recombinant Human and Mouse Tumor Necrosis Factor- α ," <i>Cellular Immunology</i> , 152:556-566 (1993). | |
| | AC10 | Boyle, P., et al., "The 85 Monoclonal Human Autoantibody Binds to Cell Surface TNF α on Human Lymphoid Cells and Cell Lines and Appears to Recognize a Novel Epitope," <i>Cellular Immunology</i> , 152:569-581 (1993). | |
| | AK11 | Shmehar, K.C.F., et al., "Generation And Characterization Of Hamster Monoclonal Antibodies That Neutralize Murine Tumor Necrosis Factors," <i>The Journal of Immunology</i> , 142(11):3884-3893 (1989). | |
| | AG11 | Jacob, C.O., et al., "Tumour necrosis factor- α in murine autoimmune 'lupus' nephritis," <i>Nature</i> , 331:356-358 (1988). | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| EXAMINER <i>Karin A. Gantella</i> | | DATE CONSIDERED 7/15/2004 | |